- Liquid Levodopa/Carbidopa: Old Solution, Forgotten Complication
-
Vijiaratnam N, Cheng S, Bertram KL, Williams D
- KMID: 2395017
- J Mov Disord.
- 2017 Sep;10(3):164-165.
- doi: 10.14802/jmd.17024
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- The Effect of Levodopa on Akinetic Mutism in Bilateral Anterior Cerebral Artery Infarction: A case report
-
Kim DY, Park CI, Ohn SH, Lim JY
- KMID: 2324527
- J Korean Acad Rehabil Med.
- 2007 Apr;31(2):238-242.
Akinetic mutism is a clinical syndrome in which the patient is unable to speak (mutism) or move (akinesia). Various brain lesions can induce akinetic mutism. We attended a 71-year-old woman... -
- CITED
-
- Close
- SHARE
-
- Close
- The Therapeutic Effect of Drug in Parkinson's Disease
-
Choi IS, Lee MS, Lee YJ, Chung WY, Lee SS, Kim WT
- KMID: 2184376
- J Korean Neurol Assoc.
- 1989 Jun;7(1):19-25.
Two hundred and four patients with Parkinson's disease initially treated wth a combination of levodopa and carbidopa ( Sinement 25-250 ) and / or anticholinergic drugs. All patients responded initially... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparative Cognitive Effects of Levo-Dopa Plus Carbidopa and Dopamine Agonist as an Initial Therapy of Parkinson's Disease
-
Park JH, Kwon OD, Choi SY, Lee DK
- KMID: 2343328
- J Korean Neurol Assoc.
- 2008 Nov;26(4):341-346.
BACKGROUND: Cognitive impairments are common in patients with Parkinson's disease (PD). However little is known about the cognitive effects of dopaminergic therapy. METHODS: The study was a single-blind prospective study of... -
- CITED
-
- Close
- SHARE
-
- Close
- Anti-Allodynic Effects of Levodopa in Neuropathic Rats
-
Park HJ, Joo HS, Kim YH, Kwon OK, Lee J, Kim ES, Moon DE
- KMID: 1503893
- Yonsei Med J.
- 2013 Mar;54(2):330-335.
- doi: 10.3349/ymj.2013.54.2.330
PURPOSE: Levodopa is the most effective anti-Parkinsonian agent. It has also been known to exhibit analgesic properties in laboratory and clinical settings. However, studies evaluating its effects on neuropathic pain... -
- CITED
-
- Close
- SHARE
-
- Close
